Acute stress disorder
diseaseOn this page
Also known as acute stress reaction
Summary
Acute stress disorder (MONDO:0003763) is a disease with 2 GWAS associations across 14 studies and 32 clinical trials. Top therapeutic interventions include propranolol, prazosin, and cyclobenzaprine hydrochloride. A subtype of anxiety disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 2
- Clinical trials: 32
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | acute stress disorder |
| Mondo ID | MONDO:0003763 |
| EFO | EFO:0005223 |
| MeSH | D000068099 |
| DOID | DOID:6088 |
| ICD-10-CM | F43.0 |
| NCIT | C92621 |
| SNOMED CT | 67195008 |
| UMLS | C0236816 |
| MedGen | 116022 |
| Is cancer (heuristic) | no |
Also known as: acute stress reaction
Data availability: 2 GWAS associations (14 studies).
Disease family
This is a subtype of anxiety disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › anxiety disorder › acute stress disorder
Related subtypes (9): separation anxiety disorder, neurocirculatory asthenia, generalized anxiety disorder, phobic disorder, neurotic disorder, panic disorder, obsessive-compulsive disorder, anxiety, mixed anxiety and depressive disorder
Subtypes (1): combat disorder
Genetics & variants
GWAS landscape
2 GWAS associations across 14 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs149368821 | 2e-09 | YBX1P1 - LINC02290 | ? | |
| rs577242570 | 5e-08 | LIN28AP1 - CACYBPP2 | G | 2.33 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90086138 | Guindo-Martinez M | 2021 | 4,314 | 52,323 | The impact of non-additive genetic associations on age-related complex diseases. |
| GCST90086139 | Guindo-Martinez M | 2021 | 4,314 | 52,323 | The impact of non-additive genetic associations on age-related complex diseases. |
| GCST90086140 | Guindo-Martinez M | 2021 | 4,314 | 52,323 | The impact of non-additive genetic associations on age-related complex diseases. |
| GCST90086141 | Guindo-Martinez M | 2021 | 4,314 | 52,323 | The impact of non-additive genetic associations on age-related complex diseases. |
| GCST90086142 | Guindo-Martinez M | 2021 | 4,314 | 52,323 | The impact of non-additive genetic associations on age-related complex diseases. |
| GCST90481784 | Verma A | 2024 | 3,533 | 439,501 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481783 | Verma A | 2024 | 1,426 | 117,164 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90077765 | Backman JD | 2021 | 669 | 331,085 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90081751 | Backman JD | 2021 | 669 | 331,085 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90077766 | Backman JD | 2021 | 637 | 328,415 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 2 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 1 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs149368821 | 14 | 66099110 | T>A,C | intron_variant | YBX1P1 - LINC02290 | 2e-09 | Tier 4: intronic/intergenic | |
| rs577242570 | 2 | 183542373 | T>C,G | 0.004 | intergenic_variant | LIN28AP1 - CACYBPP2 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Propranolol.
Clinical trials & evidence
Clinical trials
Clinical trials: 32.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 20 |
| PHASE2 | 8 |
| PHASE4 | 2 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06982183 | PHASE4 | RECRUITING | The Effects of Propranolol and Hydrocortisone on Military-Relevant Performance Outcomes |
| NCT04769297 | PHASE4 | UNKNOWN | Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic |
| NCT06636786 | PHASE2 | RECRUITING | Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) |
| NCT06943404 | PHASE2 | RECRUITING | BXCL501 After Stress to Increase Recovery Success |
| NCT01703819 | PHASE1/PHASE2 | COMPLETED | Explorative Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting in Healthy Subjects |
| NCT01703832 | PHASE1/PHASE2 | COMPLETED | Explorative Open Label Study of Efficacy Profile of Neurexan® in Experimental Acute Stress Setting in Healthy Subjects |
| NCT02602275 | PHASE2 | COMPLETED | Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands |
| NCT03045016 | PHASE2 | COMPLETED | Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder |
| NCT03152175 | PHASE2 | UNKNOWN | Posttraumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators |
| NCT04924166 | PHASE2 | COMPLETED | PTSD Prevention Using Oral Hydrocortisone |
| NCT04982211 | PHASE2 | UNKNOWN | Comparing Standard vs. Modified Reconsolidation Blockade for the Treatment of Psychological Trauma |
| NCT05057689 | PHASE2 | WITHDRAWN | Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room |
| NCT05427708 | Not specified | RECRUITING | Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety |
| NCT06318195 | Not specified | NOT_YET_RECRUITING | Condensed Digital Prolonged Exposure for Individuals Treated Within Somatic Trauma Care. |
| NCT06482567 | Not specified | RECRUITING | Promoting Improved Functioning Among People Experiencing Stressful Situations |
| NCT06502106 | Not specified | NOT_YET_RECRUITING | Internet-delivered Trauma-focused Cognitive-behavioral Therapy as an Early Intervention After Sexual Trauma |
| NCT07069478 | Not specified | RECRUITING | Cannabidiol (CBD) and Stress Response: Psychobiological Mechanisms |
| NCT07197476 | Not specified | RECRUITING | Adolescent Stress and Substance Intervention Subsequent to Trauma |
| NCT07507669 | Not specified | NOT_YET_RECRUITING | Impact of MetaCalm on Stress of Healthy People With Acute Stress |
| NCT07529379 | Not specified | RECRUITING | Breathwork and Stress: Investigating the Mechanisms of Action and Effectiveness of Breathing Interventions in Modulating the Psychophysiological Response to Acute Stress Test |
| NCT00186472 | Not specified | COMPLETED | Intervention to Decrease Anxiety in Parents of Infants in the Neonatal Intensive Care Unit (NICU) |
| NCT01085370 | Not specified | COMPLETED | Psychological Interventions in Children After Road Traffic Accidents or Burns |
| NCT02502513 | Not specified | COMPLETED | Prevention of Intrusive Memories and Posttraumatic Stress Symptoms After Emergency Cesarean Section |
| NCT03576586 | Not specified | COMPLETED | Swiss TrAumatic biRth Trial |
| NCT03812458 | Not specified | UNKNOWN | GASA-CIR Trail (Guidance and the Symptoms of Acute Stress and Anxiety in Critically Ill Patients Relatives in Intensive Care Unit) |
| NCT03954522 | Not specified | COMPLETED | The Visiting Child and His Family in ICU |
| NCT04202042 | Not specified | UNKNOWN | Post-traumatic Stress Injuries Among Paramedics and Emergency Dispatchers |
| NCT04486404 | Not specified | COMPLETED | Needs, Perceptions and Acute Stress of Healtcare Workers Caring for COVID-19 Patients in South America |
| NCT05206734 | Not specified | COMPLETED | Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health |
| NCT06277973 | Not specified | UNKNOWN | Feasibility Study of the Self-Care Immediate Stabilization Procedure (ISP) ® After a Traumatic Experience |
| NCT06390267 | Not specified | COMPLETED | Effect of Transcutaneous Auricular Neurostimulation on Cognitive Performance in a Laboratory Model of Acute Stress Reaction |
| NCT06986135 | Not specified | COMPLETED | The Effect of Breathing on Cognitive Performance and Stress |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PROPRANOLOL | 4 | 5 |
| PRAZOSIN | 4 | 3 |
| CYCLOBENZAPRINE HYDROCHLORIDE | 4 | 1 |
| HYDROCORTISONE | 4 | 1 |
| DEXPROPRANOLOL | 2 | 1 |
Related Atlas pages
- Drugs: Propranolol, Prazosin, Cyclobenzaprine, Hydrocortisone